Welcome to the Working Group on New TB Drugs Blog
Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6
On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available.
TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
World TB Day Coverage: New Combo TB Drug Trial Announced
During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID).
Summary Available! TB Clinical Trials Consultants Meeting
On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.
Posted in Front Lines of TB R&D, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast interview with Dr. Gyanu Lamicchane
Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years. In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane’s motivation to work with TB. Additional links to TB R&D news are included.
TB R&D Weekly Update: Zinc Used by Host to Fight TB
This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body’s immune response to intracellular infection by M.tb. and the microbe’s strategy to subvert this defense. Additional links to TB R&D news are included.
USAID Head: TB Drug Research Critical in Turning Tide Against Epidemic
Dr. Rajiv Shah, Administrator of the United States Agency for International Development (USAID) presented the most recent David E. Barmes Global Health Lecture on Tuesday, February 15, 2011 on the NIH Campus in Bethesda, Maryland.
WGND 2010 Annual Meeting: Panel Discussion
Following the guest speakers, several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. We recap the presentations here and offer .pdf downloads of the original presentations.
WGND 2010 Annual Meeting Recap
Thank you to everyone who was able to join us in Berlin. This recap summarizes the work that was presented at our Annual Meeting on November 12. Co-chairs of WGND, Mel Spigelmen and Bill Bishai opened the annual meeting by welcoming the attendees and briefly reviewing the agenda for the meeting.
Report from NIH/NIAID Town Hall on HIV/AIDS Clinical Trial Network Restructuring
Lisan Parker was on hand at the Town Hall Meeting to Examine the Restructuring of the NIH/NIAID Clinical Trials Networks for HIV/AIDS & Other Infectious Diseases and filed this report.
-
Toppix TB News- Detection of second-line drug resistance in mycobacterium... 24 May 2013
- Effect of Isoniazid Shortage on TB Care 24 May 2013
- Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 23 May 2013
- Impact of a Shortage of First-Line Antituberculosis Medication on... 23 May 2013
- TB, a neglected disease in Uganda 15 May 2013
